Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls-Reference-Cited by-同舟云学术

Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls

Published:2004-01-01 Issue:1 Volume:10 Page:68-75
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Kantarjian Hagop,O’Brien Susan,Cortes Jorge,Giles Francis,Shan Jianqin,Rios Mary Beth,Faderl Stefan,Verstovsek Srdan,Garcia-Manero Guillermo,Wierda William,Kornblau Steven,Ferrajoli Alessandra,Keating Michael,Talpaz Moshe

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents;American Journal of Hematology;2017-02-13

2. Emerging biomarkers in head and neck cancer in the era of genomics;Nature Reviews Clinical Oncology;2014-11-18

3. Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial;Cancer Chemotherapy and Pharmacology;2014-10-09

4. Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community setting;Current Medical Research and Opinion;2013-11-21

5. Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia;Journal of Blood Medicine;2012-11